Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

125.28 +2.46 (+2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 389,318
Open 124.04
Bid (Size) 122.25 (1)
Ask (Size) 128.40 (1)
Prev. Close 122.82
Today's Range 121.51 - 125.94
52wk Range 86.55 - 161.00
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga

Performance

YTD
-1.76%
-1.76%
1 Month
-11.12%
-11.12%
3 Month
+0.23%
+0.23%
6 Month
-6.51%
-6.51%
1 Year
+32.36%
+32.36%

More News

Read More
3 Oversold Stocks with Big RSI Rebound Potential
Via MarketBeat
Topics Economy
Exposures Interest Rates
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
Via Benzinga
$1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Topics Economy
Exposures Interest Rates
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Via Benzinga
Exposures Product Safety
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
Why Ascendis Pharma Stock Tumbled by 11% Today
Via The Motley Fool
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
Via Investor's Business Daily
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Via Benzinga
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
Via Benzinga
Exposures Product Safety
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
Via Investor's Business Daily
Exposures Product Safety
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.